These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20173587)

  • 21. Rheumatoid arthritis: principles of early treatment.
    Bresnihan B
    J Rheumatol Suppl; 2002 Nov; 66():9-12. PubMed ID: 12435163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of p16 at sites of cartilage invasion in the SCID mouse coimplantation model of rheumatoid arthritis.
    Kuenzler P; Kuchen S; Rihosková V; Michel BA; Gay RE; Neidhart M; Gay S; Seemayer CA
    Arthritis Rheum; 2003 Jul; 48(7):2069-73. PubMed ID: 12847703
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk factors for cardiovascular disease in rheumatoid arthritis: defining treatment thresholds.
    Ravindran V; Hughes RA
    J Rheumatol; 2010 Jan; 37(1):200; author reply 201-2. PubMed ID: 20040642
    [No Abstract]   [Full Text] [Related]  

  • 24. MAPK signalling in rheumatoid joint destruction: can we unravel the puzzle?
    Meyer LH; Pap T
    Arthritis Res Ther; 2005; 7(5):177-8. PubMed ID: 16207342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis.
    Kirkham B; Portek I; Lee CS; Stavros B; Lenarczyk A; Lassere M; Edmonds J
    J Rheumatol; 1999 Apr; 26(4):777-84. PubMed ID: 10229396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction.
    Mor A; Abramson SB; Pillinger MH
    Clin Immunol; 2005 May; 115(2):118-28. PubMed ID: 15885632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.
    Haringman JJ; Gerlag DM; Zwinderman AH; Smeets TJ; Kraan MC; Baeten D; McInnes IB; Bresnihan B; Tak PP
    Ann Rheum Dis; 2005 Jun; 64(6):834-8. PubMed ID: 15576415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it time for a European consensus on the pharmacological management of early RA?
    Emery P
    J Rheumatol Suppl; 2002 Nov; 66():1-2. PubMed ID: 12435161
    [No Abstract]   [Full Text] [Related]  

  • 29. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis.
    Tolboom TC; van der Helm-Van Mil AH; Nelissen RG; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Rheum; 2005 Jul; 52(7):1999-2002. PubMed ID: 15986342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatoid arthritis: new concepts in disease evolution, pathogenesis, and treatment.
    Paget SA
    Semin Arthroplasty; 1995 Jul; 6(3):132-44. PubMed ID: 10163520
    [No Abstract]   [Full Text] [Related]  

  • 31. Improvement criteria--clinical and statistical significance: comment on the article by Pincus and Stein.
    van Gestel AM; van Riel PL
    Arthritis Rheum; 2000 Jul; 43(7):1658-60. PubMed ID: 10902775
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnosis and management of rheumatoid arthritis.
    Rindfleisch JA; Muller D
    Am Fam Physician; 2005 Sep; 72(6):1037-47. PubMed ID: 16190501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression in early rheumatoid arthritis.
    Combe B
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rheumatoid arthritis: targeting the proliferative fibroblasts.
    Kramer I; Wibulswas A; Croft D; Genot E
    Prog Cell Cycle Res; 2003; 5():59-70. PubMed ID: 14593701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 36. Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
    Kremer J
    Arthritis Rheum; 2005 Oct; 53(5):636-8. PubMed ID: 16208649
    [No Abstract]   [Full Text] [Related]  

  • 37. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.
    Ballara S; Taylor PC; Reusch P; Marmé D; Feldmann M; Maini RN; Paleolog EM
    Arthritis Rheum; 2001 Sep; 44(9):2055-64. PubMed ID: 11592367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations.
    Kinne RW; Kunisch E; Beensen V; Zimmermann T; Emmrich F; Petrow P; Lungershausen W; Hein G; Braun RK; Foerster M; Kroegel C; Winter R; Liesaus E; Fuhrmann RA; Roth A; Claussen U; Liehr T
    Genes Chromosomes Cancer; 2003 Sep; 38(1):53-67. PubMed ID: 12874786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 40. Antifolate/antiproliferative therapy in rheumatoid arthritis.
    Cutolo M
    Clin Exp Rheumatol; 2005; 23(4):435-7. PubMed ID: 16095109
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.